Evidence map›Paper›PMID 40097759›Full record

ReviewMedical oncology (Northwood, London, England)2025

Nanomedicine innovations in colon and rectal cancer: advances in targeted drug and gene delivery systems.

Sobia Razzaq, Iqra Fatima, Zeinab Moafian, Abbas Rahdar, Sonia Fathi-Karkan, Zelal Kharaba, Maryam Shirzad, Ahmad Khan, Sadanand Pandey

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sobia RazzaqSchool of Pharmacy, University of Management and Technology, Lahore, Punjab, Pakistan.
Iqra FatimaDepartment of Pharmacy, Quaid-i-Azam University, Islamabad, 45320, Pakistan.
Zeinab MoafianDepartment of Chemistry and Biochemistry, University of Delaware, Newark, USA.
Abbas RahdarDepartment of Physics, Faculty of Sciences, University of Zabol, Zabol, 538-98615, Iran. a.rahdar@uoz.ir.
Sonia Fathi-KarkanNatural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, 94531-55166, Iran. Soniafathi92@gmail.com.
Zelal KharabaDepartment of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, UAE.
Maryam ShirzadNanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Ahmad KhanDepartment of Pharmacy, Quaid-i-Azam University, Islamabad, 45320, Pakistan. akhan@qau.edu.pk.
Sadanand PandeySchool of Bioengineering and Food Technology, Faculty of Applied Sciences and Biotechnology, Shoolini University, Solan, 173229, Himachal Pradesh, India. Sadanand.au@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology has revolutionized cancer diagnostics and therapy, offering unprecedented possibilities to overcome the constraints of conventional treatments. This study provides a detailed overview of the current progress and difficulties in the creation of nanostructured materials, with a specific emphasis on their use in drug and gene delivery systems. The study examines tactics that attempt to improve the effectiveness and safety of chemotherapeutic drugs such as doxorubicin (Dox) by focusing on the potential of antibody-drug conjugates and functionalized nanoparticles. Moreover, it clarifies the challenges encountered in administering nanoparticles orally for gastrointestinal treatments, emphasizing the crucial physicochemical properties that affect their behavior in the gastrointestinal system. This study highlights the transformational potential of nanostructured materials in precision oncology by examining advanced breakthroughs such cell membrane-camouflaged nanoparticles and inorganic nanoparticles designed for gastrointestinal disorders. The text investigates the processes involved in the absorption of nanoparticles and their destruction in lysosomes, revealing the many methods in which enterocytes take up these particles. This study strongly supports the use of advanced nanoparticle-based methods to reduce the harmful effects on the whole body and improve the effectiveness of therapy, based on a thorough examination of current experiments on animals and humans. The main objective of this paper is to provide a fundamental comprehension that will stimulate more investigation and practical use in the field of cancer nanomedicine, advancing its boundaries.

Indexed as

Antineoplastic AgentsColonic NeoplasmsDrug Delivery SystemsGene Transfer TechniquesNanomedicineRectal NeoplasmsAnimalsHumansNanoparticlesAntineoplastic AgentsColorectal cancer (CRC)Drug delivery systemsGen deliveryNanotechnologyTargeted chemotherapy

Identifiers

PMID40097759

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.